Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:24 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Post-operative Pain Management in Children With Supracondylar Humerus Fractures
NCT05640674 · Baylor College of Medicine · PHASE4 · terminated · last registry update 2026-02-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “After reviewing our enrollment numbers and feasibility, we have decided to close the study due to low enrollment.” | – | Registry record, Baylor College of Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGS2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-09Also stopped (terminated): Apsen Farmaceutica S.A., Fixed Dose Combination + Etodolac (NCT03127592)
- 2025-07-18Results posted on the registry: Columbia University, I 124-Evuzamitide (NCT05635045)
- 2025-03-11Phase 3 first posted: Teikoku Seiyaku Co., Ltd., Esflurbiprofen Topical System (EFTS) (NCT06871046)
- 2025-03-10Phase 3 first posted: Teikoku Seiyaku Co., Ltd., Esflurbiprofen Topical System (EFTS) + Placebo Patch (NCT06866613)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision